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Bordetella pertussis causes whooping cough, a severe respiratory-
tract infection. The disease affects all age groups of people, but
its severity is greatest in young children. In spite of vaccination
programmes, whooping cough epidemics continue to occur
[1,2].
Erythromycin (main component, erythromycin A) is
regarded as the antibiotic of choice for treatment and post-
exposure prophylaxis of B. pertussis infection. Widespread use
of macrolides may lead to changes in susceptibility patterns
and the emergence of resistance in earlier susceptible bacteria.
Resistance of B. pertussis to erythromycin had not previously
been reported until recently,when two B. pertussis isolates that
were resistant to this antibiotic were found in the United States
[3,4]. The data may indicate a necessity to evaluate the activity
of new antimicrobial agents against B. pertussis.
The aim of this study was to compare the susceptibility to
macrolides of B. pertussis strains isolated in 1968 and 30 years
later in Poland.
The analysed strains of B. pertussis were isolated from the
nasopharynx of children with whooping cough in 1968 (n = 21)
and in the years 1997–98 (n = 34). The B. pertussis isolates from
1968 were collected at the Pertussis Laboratory, National
Institute of Hygiene and the strains isolated in the years 1997–
98 were collected at Warsaw Sanitary and Epidemiological
Station. Macrolide standards of known potency were applied
as follows: erythromycin (USP, Rockville, DC, USA,
945 U/mg), azithromycin (Pliva, Zagreb, Croatia, 96.9%), cla-
rithromycin (Abbott Laboratories, Rungis Cedex, France,
992 U/mg), dirithromycin (Eli Lilly, Indiana, IN, USA, 96.9%),
oleandomycin (Sigma, St. Louis, MI, USA, 95%), roxi-
thromycin (Hoechst Marion Roussel, Paris La Defense Cedex,
France, 100%), spiramycin (Rhone Poulenc Rorer, Antony
Cedex, France, 4375 U/mg) and josamycin (Virbac, Carros,
France, 999 U/mg). All B. pertussis isolates were stored in a
freeze-dried form. The antibiotic agar dilution method was
used. Before analysis the strains were subcultured twice on
Bordet-Gengou agar supplemented with 30% sheep blood and
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incubated at 36 °C for 48 h. Serial twofold dilutions of antibiotic
concentrations (final concentrations from 8 mg/L to
0.008 mg/L) were added to the Bordet Gengou agar sup-
plemented with 5% horse blood. Plates were inoculated with a
standardized inoculum giving a final concentration of 104 CFU
and incubated at 36 °C for 96 h. The results were read after 72
and 96 h. Macrolide minimum inhibitory concentration (MIC)
was interpreted as the lowest concentration of antimicrobial
agent that completely inhibited bacterial growth. Staphylococcus
aureus ATCC 29213 was used as a control strain.
The minimum concentrations of macrolides which inhibited
growth of B. pertussis strains were calculated for 50 and 90% of
isolates (MIC50, MIC90, respectively) obtained in 1968 and
30 years later (Table 1). The MIC90 values of clarithromycin,
josamycin and oleandomycin for B. pertussis strains isolated in
the years 1997–98 were one dilution higher in comparison with
those for these antibiotics and B. pertussis isolates recovered in
1968. One dilution higher MIC50 values of oleandomycin was
also observed for B. pertussis strains from the years 1997–98 in
comparison with the MIC50 values of the antibiotic and B.
pertussis isolates obtained in 1968. These were the only dif-
ferences in the pattern of susceptibility to macrolides between
the B. pertussis strains isolated in the years 1997–98 and in 1968.
The most active antimicrobial agent against all strains was
azithromycin (MIC90, 0.06 mg/L) followed by clarithromycin,
dirithromycin, erythromycin, roxithromycin and josamycin.
The MIC range, MIC50 and MIC90 values of erythromycin
were the same for B. pertussis isolates recovered in 1968 as for
those recovered in the years 1997–98. In the present study
oleandomycin and spiramycin had the least activity. None of
B. pertussis isolates was found to possess a macrolide
MIC  8 mg/L.
Antimicrobial susceptibility testing of slow-growing, fas-
tidious bacteria such as B. pertussis is not standardized. A review
of the publications [4–7] shows that widely divergent methods
have been employed, which makes comparison of different
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Table 1 Activities of
macrolides against B. pertussis
strains isolated in 1968
and 1997–98
MIC (mg/L)
Strains Antibiotic Range 50% 90%
B. pertussis strains Erythromycin 0.06–0.25 0.06 0.125
isolated in 1968 Azithromycin 0.03–0.125 0.06 0.06
n = 21 Clarithromycin 0.016–0.125 0.06 0.06
Dirithromycin 0.03–0.125 0.06 0.125
Oleandomycin 1–2 1 2
Roxithromycin 0.06–0.25 0.125 0.25
Spiramycin 4–8 4 8
Josamycin 0.06–0.5 0.25 0.25
B. pertussis strains Erythromycin 0.06–0.25 0.06 0.125
isolated in 1997–98 Azithromycin 0.03–0.125 0.06 0.06
n = 34 Clarithromycin 0.016–0.125 0.06 0.125
Dirithromycin 0.03–0.125 0.06 0.125
Oleandomycin 1–4 2 4
Roxithromycin 0.06–0.5 0.125 0.25
Spiramycin 4–8 4 8
Josamycin 0.06–0.5 0.25 0.5
results rather difficult. In the present study Bordet-Gengou agar
supplemented with 5% horse blood was chosen for testing the
activity of macrolides against B. pertussis. Considerably better
growth of test organisms and readability of plates were obtained
with this medium in comparison with those from Mueller-
Hinton agar which contained 5% horse blood.
The macrolides, a large group of antibiotics consist of a
macrocyclic lactone ring substituted with two sugars, one of
which is an aminosugar [8]. Erythromycin A is a 14-membered
ring macrolide which was developed many years ago for clinical
use (treatment of respiratory tract infections). The MIC of
erythromycin against B. pertussis strains usually ranges from
0.125 mg/L to 0.5 mg/L [9]. In the present study ery-
thromycin had good inhibitory activity (MIC90, 0.125 mg/L)
against all B. pertussis strains. Bannatyne and Cheung [10] also
noted no change in the erythromycin susceptibility of B. per-
tussis strains isolated in the years 1960–81. It supports the con-
tinued role of erythromycin as the antibiotic of choice for
B.pertussis infection treatment. Recently, a number of ery-
thromycin A derivatives have been synthesized including cla-
rithromycin, dirithromycin and roxithromycin. Incorporation
of a methyl-substituted nitrogen into the lactone ring of ery-
thromycin A has produced a 15-membered ring macrolide,
azithromycin, which belongs to the azalides. Azithromycin
exhibits increased potency against Gram-negative bacteria. In
the present study azithromycin and clarithromycin showed the
highest activity against B. pertussis. The MIC range (0.016–
0.125 mg/L) and low MIC50 (0.06 mg/L) obtained for cla-
rithromycin had the same value as that observed by Hoppe
and Bryskier [7]. The data indicate that these new macrolides,
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azithromycin and clarithromycin, may become an alternative
to erythromycin for the treatment of pertussis.
The other antibiotics analysed belong to 14-membered ring
macrolides, with the exception of spiramycin and josamycin,
which are two 16-membered ring structures. Erythromycin
and its derivatives seem to be more active against B. pertussis,
than the naturally produced macrolides oleandomycin, spira-
mycin and josamycin. Oleandomycin and spiramycin with
MIC90 values that were 32-fold and 64-fold higher,
respectively, than the erythromycin MIC90 value are not
recommended for whooping cough treatment.
In conclusion, the macrolide susceptibility of B. pertussis
strains isolated in the years 1997–98 did not significantly differ
from the values obtained for isolates recovered in 1968, which
is evidence of the genetic stability of this microorganism to
antibiotic treatment.
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